The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $361.01

Today's change+0.05 +0.01%
Updated February 24 4:00 PM EST. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $361.01

Today's change+0.05 +0.01%
Updated February 24 4:00 PM EST. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc up slightly

Regeneron Pharmaceuticals Inc closed up just (U.S.)$0.05 Friday to (U.S.)$361.01. Shares have lost 2.74% over the last five days, but are unchanged over the last year to date. This security has underperformed the S&P 500 by 30.96% during the last year.

Key company metrics

  • Open(U.S.) $359.88
  • Previous close(U.S.) $360.96
  • High(U.S.) $361.08
  • Low(U.S.) $355.00
  • Bid / Ask(U.S.) $351.00 / (U.S.) $361.00
  • YTD % change-1.66%
  • Volume782,594
  • Average volume (10-day)1,012,865
  • Average volume (1-month)909,212
  • Average volume (3-month)953,895
  • 52-week range(U.S.) $325.35 to (U.S.) $452.96
  • Beta1.36
  • Trailing P/E46.82×
  • P/E 1 year forward27.81×
  • Forward PEG1.49×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $7.71
Updated February 24 4:00 PM EST. Delayed by at least 15 minutes.
S&P TSX1.57%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue1,2271,2201,2131,201
Total other revenue--------
Total revenue1,2271,2201,2131,201
Gross profit1,1521,1761,1441,089
Total cost of revenue754469112
Total operating expense880857921872
Selling / general / administrative326270292290
Research & development479543560470
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income347363292329
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax342366292330
Income after tax253265196181
Income tax, total8810196149
Net income253265196181
Total adjustments to net income--------
Net income before extra. items253265196181
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items253265196181
Inc. avail. to common incl. extra. items253265196181
Diluted net income253265196182
Dilution adjustment0000
Diluted weighted average shares116116116116
Diluted EPS excluding extraordinary itemsvalue per share2.192.271.691.56
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share2.192.271.691.56